Estimated weight is not a reliable measure for dosing tissue plasminogen activator for thrombolysis in acute ischaemic stroke

Abstract

Get full access to this article

View all access options for this article.

References

Adams

Jr del Zoppo

Alberts

. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007; 115: e478–e534.

Levy

Brott

Haley

Jr . Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994; 25: 291–297.

Breuer

Nowe

Huttner

. Weight approximation in stroke before thrombolysis: the WAIST-Study: a prospective observational “dose-finding” study. Stroke 2010; 41: 2867–2871.

Garcia-Pastor

Diaz-Otero

Funes-Molina

. Tissue plasminogen activator for acute ischemic stroke: calculation of dose based on estimated patient weight can increase the risk of cerebral bleeding. J Thromb Thrombolysis 2015; 40: 347–352.

Sahlas

Gould

Swartz

. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes. J Stroke Cerebrovasc Dis 2014; 23: 155–159.

Hacke

Kaste

Fieschi

. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–1025.